Advocacy & Compliance

Healthesystems’ Advocacy & Compliance experts are essential in the management of pharmacy and ancillary benefits for our clients. By tracking and influencing regulatory activity, our team stays ahead of evolving trends and identifies opportunities to advocate on behalf of our clients, their injured workers, and the broader industry.

Go to Regulatory Recap News

Subscribe for Weekly Updates

The Advocacy &  Compliance Team

Monitors and reports on proposed and pending regulatory changes that impact workers' comp, helping shape effective program strategies

Advocates for fair and balanced public policy through proactive engagement with regulators, customers, and other stakeholders throughout the rulemaking lifecycle

Supports operational compliance by providing guidance to internal stakeholders and external partners during the implementation of new regulatory changes

Regulatory Recap

A weekly e-newsletter informed by the Advocacy & Compliance team to help keep our clients and industry contacts in the know on the latest legislation and policy updates impacting workers’ comp.

Subscribe

Spotlight

Marijuana

Marijuana Rescheduled by DOJ and DEA

FDA-approved products and state-regulated medical products are now Schedule III, effective immediately.

Read More →

April 27, 2026

Spotlight

Advocacy Opportunity Training Opportunity

Insights from the 2026 IAIABC Forum

Discussions centered around evolving approaches to carrier compliance and oversight, reflecting an increasing shift toward data-driven system alignment.

Read More →

April 27, 2026

Spotlight

Advocacy Opportunity Training Opportunity

Insights From the Delaware/Pennsylvania WCRB Forum

Among many educational sessions, Sandy Shtab, Healthesystems VP of Industry and State Affairs, joined a panel on Medical Experience.

Read More →

April 27, 2026

Advocacy Opportunity Ancillary Services Treatment Guidelines

Montana Proposes Updates to Formulary and Fee Schedule, Requesting Stakeholder Feedback

A remote hearing will be held on May 28th, with comments accepted through June 5th. If enacted, changes will take effect July 1st.

Read More →

May 18, 2026

Psychedelics

Oklahoma Enacts Law for Ibogaine Clinical Trials

Effective November 1st, the Department of Health can enter into contracts with drug developers to conduct ibogaine clinical trials.

Read More →

May 18, 2026

Psychedelics

Connecticut Could Soon Expand Psychedelic Pilot Program

Previously limited to veterans and other specific populations, the bill could apply to any adult that meets clinical eligibility criteria.

Read More →

May 18, 2026

Mental Health Opioids Psychedelics

Louisiana Considers Psychedelic-Assisted Therapy Program

Psilocybin and ibogaine clinical trials would target opioid use disorder and treatment-resistant mental health conditions.

Read More →

May 18, 2026

Mental Health Psychedelics

Minnesota Considers Psychedelics Therapy Program

A three-year pilot program would allow for 1,000 patients annually to receive treatment for PTSD, depression, chronic pain, and more.

Read More →

May 18, 2026

Claim Costs Claim Data

NCCI Publishes 2026 State of the Line Report

While claim frequency is declining, severity is increasing, with injured workers receiving more care or more complex treatment.

Read More →

May 18, 2026

1 2 3 … 53 Next »

Subscribe to Regulatory Recap

Get weekly legislation & policy updates straight to your inbox.

hello world!

Further resources you may be interested in

Additional articles and updates from Healthesystems related to policy shaping workers’ comp.

Rescheduling Questions: How the Marijuana Landscape Could Soon Change

The rescheduling of marijuana may introduce significant implications for clinical research, drug development, and downstream utilization.

White House Issues Executive Order on Psychedelics

The order seeks to accelerate clinical trials, data sharing, drug approvals, and possibly rescheduling.

Texas Approves Audit of Topical Analgesics

After soliciting stakeholder feedback on possible audit topics, the DWC prioritized a study of topical analgesics by the Medical Quality Review Panel.

Rescheduling Questions: How the Marijuana Landscape Could Soon Change

The rescheduling of marijuana may introduced significant implications for clinical research, drug development, and downstream utilization.

State of the Nation: Summer 2026

Healthesystems’ Sandy Shtab examines key workers’ comp policy trends, from PBM regulation and AI oversight to marijuana rescheduling and injured worker engagement.